Steven P. Dunn

Steven P. Dunn

Auto-generated profile, based on publicly available information

Steven P. Dunn

Department of Pharmacy Services, UVA Health, University of Virginia, Charlottesville, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in JACC
Verified
Journal Article
Closed access
SDSteven P. Dunn
Steven P. Dunn
KBKim K. Birtcher
Kim K. Birtcher
CBCraig J. Beavers
Craig J. Beavers
WBWilliam L. Baker
William L. Baker
SBSara D. Brouse
Sara D. Brouse
MWMary Norine Walsh
Mary Norine Walsh

4 November 2012 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
AGA. Kendall Gross
A. Kendall Gross
SDSteven P. Dunn
Steven P. Dunn
DFDavid J. Feola
David J. Feola
CMCraig A. Martin
Craig A. Martin
RCRichard Charnigo
Richard Charnigo
SSSusan S. Smyth
Susan S. Smyth

1 October 2021 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
CBCraig J. Beavers
Craig J. Beavers
RDRobert J. DiDomenico
Robert J. DiDomenico
SDSteven P. Dunn
Steven P. Dunn
JCJenna Cox
Jenna Cox
LTLong To
Long To
DJDouglas L. Jennings
Douglas L. Jennings

23 January 2013 in Journal of the American Heart Association
Verified
Journal Article
Open access
SDSteven P. Dunn
Steven P. Dunn
SSSteven R. Steinhubl
Steven R. Steinhubl
DBDeborah Bauer
Deborah Bauer
RCRichard J. Charnigo
Richard J. Charnigo
PBPeter B. Berger
Peter B. Berger
ETEric J. Topol
Eric J. Topol
Background: Proton pump inhibitors ( PPI s) may interfere with the metabolic activation of clopidogrel via inhibition of cytochrome P450 2C19, but the clinical implications remain unclear. Methods and Results: The impact of PPI use on the 1‐year primary end point (ischemic stroke, myocardial infarction [ MI ], or vascular death) in the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial and the 28‐day (all‐cause death, MI , or urgent target vessel revascularization) and 1‐year (all‐cause death, MI , or stroke) primary end points in the Clopidogrel for Reduction of Events During Observation (CREDO) trial were examined. Clopidogrel appeared to elevate risk for the primary end point in CAPRIE among PPI users (estimated hazard ratio [ EHR ] 2.66, 95% CI 0.94 to 7.50) while lowering it for non‐ PPI users ( EHR 0.90, 95% CI 0.83 to 0.99, interaction P =0.047). Moreover, PPI use was associated with worse outcomes in patients receiving clopidogrel ( EHR 2.39, 95% CI 1.74 to 3.28) but not aspirin ( EHR 1.04, 95% CI 0.70 to 1.57, interaction P =0.001). Clopidogrel did not significantly alter risk for the 1‐year primary end point in CREDO among PPI users ( EHR 0.82, 95% CI 0.48 to 1.40) while lowering it for non‐ PPI users ( EHR 0.71, 95% CI 0.52 to 0.98, interaction P =0.682). Also, PPI use was associated with worse outcomes in both patients receiving clopidogrel ( EHR 1.67, 95% CI 1.06 to 2.64) and those receiving placebo ( EHR 1.56, 95% CI 1.06 to 2.30, interaction P =0.811). Conclusions: In CREDO , the efficacy of clopidogrel was not significantly affected by PPI use. However, in CAPRIE , clopidogrel was beneficial to non‐ PPI users while apparently harmful to PPI users. Whether this negative interaction is clinically important for patients receiving clopidogrel without aspirin needs further study.

28 April 2022 in Clinical Cardiology
Verified
Journal Article
Open access
MRMary E. Roth
Mary E. Roth
MCMelissa E. Chinn
Melissa E. Chinn
SDSteven P. Dunn
Steven P. Dunn
KBKenneth C Bilchick
Kenneth C Bilchick
SMSula Mazimba
Sula Mazimba
Background: Gout is a common comorbidity in heart failure (HF) patients and is frequently associated with acute exacerbations during treatment for decompensated HF. Although colchicine is often used to manage acute gout in HF patients, its impact on clinical outcomes when used during acute decompensated HF is unknown.Methods: This was a single center, retrospective study of hospitalized patients treated for an acute HF exacerbation with and without acute gout flare between March 2011 and December 2020. We assessed clinical outcomes in patients treated with colchicine for a gout flare compared to those who did not experience a gout flare or receive colchicine. The primary outcome was in‐hospital all‐cause mortality.Results: Among 1047 patient encounters for acute HF during the study period, there were 237 encounters (22.7%) where the patient also received colchicine for acute gout during admission. In‐hospital all‐cause mortality was significantly reduced in the colchicine group compared with the control group (2.1% vs. 6.5%, p = .009). The colchicine group had increased length of stay (9.93 vs. 7.96 days, p < .001) but no significant difference in 30‐day readmissions (21.5% vs. 19.5%, p = .495). In a Cox proportional hazards model adjusted for age, inpatient colchicine use was associated with improved survival to discharge (hazards ratio [HR] 0.163, 95% confidence interval [CI] 0.051−0.525, p = .002) and a reduced rate of in‐hospital CV mortality (HR 0.184, 95% CI 0.044−0.770, p = .021).Conclusion: Among patients with a HF exacerbation, treatment with colchicine for a gout flare was associated with significantly lower in‐hospital mortality compared with those not treated for acute gout.

1 May 2009 in Coronary Artery Disease
Verified
Journal Article
Open access
Julie H OestreichJulie H Oestreich
Julie H Oestreich
JHJohn Holt
John Holt
SDSteven P. Dunn
Steven P. Dunn
SSSusan S. Smyth
Susan S. Smyth
CCCharles L. Campbell
Charles L. Campbell
SSSteven R. Steinhubl
Steven R. Steinhubl
Variable platelet response to clopidogrel has been widely observed. Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes. This study examined the platelet function effects of increasing the maintenance clopidogrel dose from 75 to 150 mg/day with a focus on inter-individual response. Twenty patients with known coronary artery disease receiving 75 mg/day clopidogrel were recruited and given 150 mg/day clopidogrel for 30 days, then returned to 75 mg/day for an additional 30 days. Platelet function was assessed through light-transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay at baseline, 30 days, and 60 days. Mean platelet inhibition was significantly improved with the increased maintenance dose when measured by the VerifyNow P2Y12 assay (P2Y12 reaction units: 191±15 vs. 158±17, P=0.013), but not when measured by LTA (LTA-adenosine diphosphate 5: 40±3 vs. 36±3, P = 0.11; LTA-adenosine diphosphate 20: 50±3 vs. 47±3, P = 0.23). However, only 50% of individual patients experienced improved platelet inhibition, as measured by the VerifyNow P2Y12 assay, when treated with the increased maintenance dose. Furthermore, poor baseline platelet response did not predict improved responsiveness at the increased dose. Despite changing the population's mean antiplatelet response, an increased maintenance dose of clopidogrel did not improve antiplatelet response in a substantial number of patients; nor did baseline platelet function predict response to a higher maintenance dose.